Summary Anergis SA (Anergis) is a clinical stage biopharmaceutical company that discovers, develops and markets immunotherapy products.The company uses synthetic, pharmaceutical-grade contiguous overlapping peptide to derive allergy immunotherapeutics from its proprietary long peptide technology platform.
Its products comprise Aller T, Aller R and AllerDM.The company’s Aller R is a COP allergy vaccine for patients with moderate to severe allergy to ragweed pollen.
Its AllerDM is a COP allergy vaccine for patients with house dust mite allergy.The company operates in Japan, China, Switzerland and others.
Anergis is headquartered in Lausanne, Switzerland.
Anergis SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Market Introduction Allergen immunotherapy, also known as hypo-sensitization or desensitization, is a medical treatment for allergies.Measured doses of allergens are given to the patient resulting in reduced inflammation, which causes immune system to become less sensitive to the substance by blocking antibody function. Allergy immunotherapy...
The South and Central America Amniotic Membrane market is expected to reach US$ 85.3 million by 2027 from US$ 55.6 million in 2019. The market is estimated to grow with a CAGR of 5.7% from 2020 to 2027. The growth of the market is driven by factors such as the growing applications of Amniotic Membrane along with rising of target population....
Posterior Uveitis Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Posterior Uveitis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Posterior Uveitis Clinical trials scenario.This report provides top line data relating to the clinical trials...
House Dust Mite Allergy Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “House Dust Mite Allergy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of House Dust Mite Allergy Clinical trials scenario.This report provides top line data relating...
266 pages •
By The Business Research Company
• Dec 2020
Filgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID 19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global Filgrastim Biosimilars market. Description: Where is the largest and fastest growing market...
The global cell line development serum market is expected to reach US$ 1,467.92 million by 2027 from US$ 915.58 million in 2019. The market is estimated to grow at a CAGR of 6.1% from 2020 to 2027. Increasing adoption of regenerative medicines, favorable reimbursement policy for the rising R&D investments, and collaborations among the pharmaceutical...
Placenta Growth Factor - Pipeline Review, H2 2020 Summary According to the recently published report ’Placenta Growth Factor - Pipeline Review, H2 2020’; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 27 molecules. Placenta...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.